<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05007145</url>
  </required_header>
  <id_info>
    <org_study_id>OBU-FJ-EC-II-007</org_study_id>
    <nct_id>NCT05007145</nct_id>
  </id_info>
  <brief_title>PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma</brief_title>
  <acronym>REVO</acronym>
  <official_title>A Randomized, Open-label, Phase II Study of PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy Versus Neoadjuvant Chemoradiotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fujian Cancer Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Suzhou Suncadia Biopharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Fujian Cancer Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to explore the efficacy and safety of compare the efficacy and&#xD;
      safety of PD-1 inhibitor and chemotherapy（treatment group） with chemoradiotherapy（control&#xD;
      group） in neoadjuvant treatment of resectable thoracic esophageal squamous cell carcinoma.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized, open-label, phase II study of PD-1 inhibitor combined With neoadjuvant&#xD;
      chemotherapy versus neoadjuvant chemoradiotherapy in subjects With resectable locally&#xD;
      advanced thoracic esophageal squamous cell carcinoma. The patients will be divided into two&#xD;
      groups(1:1). In the treatment group, PD-1 inhibitor ,albumin-bound paclitaxel and cisplatin&#xD;
      will be given every 3 weeks for 2-4 cycles as neoadjuvant therapy. In the control gourp,&#xD;
      albumin-bound paclitaxel and cisplatin will be given every 3 weeks for 2 cycles as&#xD;
      neoadjuvant therapy.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 15, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">August 31, 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathologic complete response (pCR) rate</measure>
    <time_frame>Within 14 working days after surgery</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>Within 14 working days after surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>OS is defined as the time from randomization until death from any cause.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Free Survival (DFS)</measure>
    <time_frame>Up to 8 years</time_frame>
    <description>The time from the first day of the date of surgery to local or distant recurrence, or death caused by any cause, whichever occurs first;</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">92</enrollment>
  <condition>Esophageal Neoplasms</condition>
  <condition>Esophageal Squamous Cell Carcinoma</condition>
  <arm_group>
    <arm_group_label>PD-1 Inhibitor+albumin-bound paclitaxel+cisplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive PD-1 Inhibitor 200mg on Day 1 every 3 weeks (Q3W), albumin-bound paclitaxel 125 mg/m^2 on Day 1, 8 Q3W, and cisplatin 75 mg/m^2 on Day 1 Q3W, a total of 2-4 cycles，followed by surgery.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Albumin-bound paclitaxel+cisplatin+radiotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants receive albumin-bound paclitaxel 125 mg/m^2 on Day 1, 8 Q3W, and cisplatin 75 mg/m^2 on Day 1 Q3W, a total of 2 cycles combined with radiotherapy(40Gy/2Gy),followed by surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-1 inhibitor</intervention_name>
    <description>PD-1 Inhibitor 200mg D1 Q3W</description>
    <arm_group_label>PD-1 Inhibitor+albumin-bound paclitaxel+cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Albumin-Bound Paclitaxel</intervention_name>
    <description>125 mg/m^2 D1/D8 Q3W</description>
    <arm_group_label>Albumin-bound paclitaxel+cisplatin+radiotherapy</arm_group_label>
    <arm_group_label>PD-1 Inhibitor+albumin-bound paclitaxel+cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <description>75 mg/m^2 D1 Q3W</description>
    <arm_group_label>Albumin-bound paclitaxel+cisplatin+radiotherapy</arm_group_label>
    <arm_group_label>PD-1 Inhibitor+albumin-bound paclitaxel+cisplatin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Radiation</intervention_name>
    <description>40Gy/2.0Gy</description>
    <arm_group_label>Albumin-bound paclitaxel+cisplatin+radiotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Volunteered to participate in the study, signed the informed consent form;&#xD;
&#xD;
          2. Histologically or cytological confirmed esophageal squamous cell carcinoma;&#xD;
&#xD;
          3. Patients with resectable disease of primary tumor in thoracic esophagus&#xD;
             (cT1b-T3N1-3M0, cT3N0M0) evaluated by CT/MRI/EUS;&#xD;
&#xD;
          4. Expected R0 resection;&#xD;
&#xD;
          5. Aged 18-75 years, male or female;&#xD;
&#xD;
          6. ECOG PS 0-1;&#xD;
&#xD;
          7. Without prior treatments including surgery, chemotherapy, radiotherapy, and targeting&#xD;
             treatment for esophageal cancer;&#xD;
&#xD;
          8. Surgery is planned after neoadjuvant treatment;&#xD;
&#xD;
          9. Without any contraindication of operation;&#xD;
&#xD;
         10. Adequate organ function as follows: 1) Routine blood test: Leukocytes &gt;=3.0x10^9/L;&#xD;
             Absolute neutrophil count &gt;=1.0x10^9/L; Platelet &gt;=80x10^9/L; Hemoglobin &gt;=90 g/L; 2)&#xD;
             Blood biochemical test: Total bilirubin &lt;=1.5 ULN; ALT &lt;=2.5 ULN; AST &lt;=2.5 ULN; Serum&#xD;
             creatinine &lt;=1.5 ULN or creatinine clearance rate &gt;=50 mL/min (Cocheroft-Gault); 3)&#xD;
             Coagulation function test: INR &lt;=1.5 ULN; APTT &lt;=1.5 ULN;&#xD;
&#xD;
         11. For females of child bearing potential, a negative serum/urine pregnancy test result&#xD;
             within 72h before study treatment. For female and male participants of reproductive&#xD;
             potential must be willing to use adequate contraception for the course of the study&#xD;
             until 3 months after the last dose of any of the drugs in the study;&#xD;
&#xD;
         12. Had good compliance and cooperated with the follow-up.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. The tumor invades the adjacent organs of the esophageal lesion (aorta or trachea);&#xD;
&#xD;
          2. Patients with supraclavicular lymph node metastasis;&#xD;
&#xD;
          3. Uncontrollable pleural effusion, pericardial effusion or ascites requiring repeated&#xD;
             drainage;&#xD;
&#xD;
          4. Poor nutritional status, BMI &lt; 18.5 Kg/m2; If corrected after nutritional support&#xD;
             before randomization, enrollment can be further considered after evaluation by the&#xD;
             principal investigator;&#xD;
&#xD;
          5. Has a history of allergy to monoclonal antibody, any component of PD-1 Inhibitor,&#xD;
             paclitaxel, cisplatin or other platinum drugs;&#xD;
&#xD;
          6. Has received or is receiving any of the following treatments: A)any anti-tumor&#xD;
             radiation, chemotherapy or other treatment drugs; B) Immunosuppressive drugs or&#xD;
             whole-body hormone drugs are being used for immunosuppressive purposes within 2 weeks&#xD;
             prior to the first use of the study drug (dose &gt; 10mg/ day prednisone or equivalent&#xD;
             dose);Inhalation or topical use of steroids and 10 mg/ day prednisone or equivalent&#xD;
             dose of adrenocortical hormone replacement is permitted in the absence of active&#xD;
             autoimmune disease; C) Received attenuated vaccine within 4 weeks before the first use&#xD;
             of the study drug; D) Major surgery or severe trauma within 4 weeks prior to the first&#xD;
             use of the study drug;&#xD;
&#xD;
          7. History of any active autoimmune disease, including but not limited to: interstitial&#xD;
             pneumonia, enteritis, hepatitis, hypohysitis, vasculitis, nephritis, hyperthyroidism,&#xD;
             hypothyroidism (may be considered after hormone replacement therapy);Patients with&#xD;
             psoriasis or childhood asthma/allergy who have been in complete remission and do not&#xD;
             need any intervention as adults may be considered for inclusion, but patients&#xD;
             requiring medical intervention with bronchodilators may not be included;&#xD;
&#xD;
          8. History of immunodeficiency, including HIV positive, or other acquired or congenital&#xD;
             immunodeficiency disease, or history of organ transplantation or allogeneic bone&#xD;
             marrow transplantation;&#xD;
&#xD;
          9. Present of poorly controlled cardiac symptoms or disease, including but not limited&#xD;
             to: (1) heart failure with NYHA class II or above (2) unstable angina, （3）myocardial&#xD;
             infarction occurred within 1 year (4) clinical significance supraventricular or&#xD;
             ventricular arrhythmias without clinical intervention or poorly controlled after&#xD;
             clinical intervention;&#xD;
&#xD;
         10. Severe infection (CTCAE &gt; 2) occurred within 4 weeks prior to the first use of the&#xD;
             study drug, such as severe pneumonia, bacteremia, infection complications requiring&#xD;
             hospitalization, etc.;Baseline chest imaging indicated active pulmonary inflammation,&#xD;
             infection signs and symptoms within 14 days prior to the first use of the study drug,&#xD;
             or the need for oral or intravenous antibiotic treatment, except prophylactic&#xD;
             antibiotic usage;&#xD;
&#xD;
         11. Patients who are found to have active pulmonary tuberculosis infection through medical&#xD;
             history or CT, or have active pulmonary tuberculosis infection history within 1 year&#xD;
             before enrollment, or have active pulmonary tuberculosis infection history more than 1&#xD;
             year before but without regular treatment;&#xD;
&#xD;
         12. Have hereditary bleeding tendency or coagulation dysfunction. There were clinically&#xD;
             significant bleeding symptoms or a clear bleeding tendency within 3 months before&#xD;
             enrollment, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, fecal occult&#xD;
             blood++ and above at baseline;&#xD;
&#xD;
         13. Active hepatitis B (HBV DNA ≥ 2000 IU/mL or 10^4 copies/mL), hepatitis C (HCV antibody&#xD;
             positive, and HCV RNA higher than the detection limit of analytical method);&#xD;
&#xD;
         14. Other malignancies diagnosed within 5 years prior to the first use of the study drug,&#xD;
             except those with a low risk of metastasis or death (5-year survival rate &gt; 90%), such&#xD;
             as adequately treated basal cell or squamous cell skin cancer or carcinoma in situ of&#xD;
             the cervix;&#xD;
&#xD;
         15. Pregnant or lactating women;&#xD;
&#xD;
         16. In the investigator's judgment, there were other factors that might have contributed&#xD;
             to the forced termination of the study, such as the need for combined treatment with&#xD;
             other serious medical conditions (including mental illness), alcohol and drug abuse,&#xD;
             family or social factors that might have affected the safety or compliance of the&#xD;
             subjects.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shuoyan Liu</last_name>
    <role>Study Chair</role>
    <affiliation>Fujian Cancer Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shuoyan Liu</last_name>
    <phone>+86 13805088816</phone>
    <email>shuoyanliu2010@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fujian Cancer Hospital</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Shuoyan Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>the Second Hospital of Longyan</name>
      <address>
        <city>Longyan</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Rongxing Liu</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>the First Hospital of Putian City</name>
      <address>
        <city>Putian</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Jiansheng Lin</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fujian Medical University 2nd Affiliated Hospital</name>
      <address>
        <city>Quanzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Zhijun Huang</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quanzhou First Hospital</name>
      <address>
        <city>Quanzhou</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Rongqi He</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>the First Affiliated Hospital of Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Xiuyi Liu</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>August 10, 2021</study_first_submitted>
  <study_first_submitted_qc>August 12, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 16, 2021</study_first_posted>
  <last_update_submitted>August 12, 2021</last_update_submitted>
  <last_update_submitted_qc>August 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Neoadjuvant</keyword>
  <keyword>Esophageal Cancer</keyword>
  <keyword>PD-1 Inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Esophageal Squamous Cell Carcinoma</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Immune Checkpoint Inhibitors</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

